Stacy Wheeler
Geschäftsführer bei VELOXIS PHARMACEUTICALS A/S
Ursprung des Netzwerks ersten Grades von Stacy Wheeler
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 19 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Stacy Wheeler
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| CORNERSTONE THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer Chairman Director/Board Member Comptroller/Controller/Auditor Corporate Officer/Principal | |
| University of Copenhagen | College/University | Doctorate Degree Undergraduate Degree Graduate Degree Graduate Degree | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Avenge Bio, Inc.
 Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | Pharmaceuticals: Major | Founder Founder | |
AlloCure, Inc.
 AlloCure, Inc. BiotechnologyHealth Technology AlloCure, Inc. develops cell therapies for the treatment of kidney diseases. It engages in developing allogeneic mesenchymal stem cell therapy for acute kidney injury. The company was founded in 2008 and is headquartered in Burlington, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| TERRASCEND CORP. | Agricultural Commodities/Milling | Director/Board Member Director/Board Member | |
| OCATA THERAPEUTICS INC | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
| TREVI THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| HERON THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Director of Finance/CFO | |
| Copenhagen Business School | College/University | Graduate Degree Undergraduate Degree | |
CMC
 CMC Miscellaneous Commercial ServicesCommercial Services Part of Universal Music Group NV, CMC is a Danish company that publishes music records. The company is located in Denmark. CMC was acquired by EMI Group Ltd., part of Universal Music Group NV from June 29, 2012 on November 01, 1997. | Miscellaneous Commercial Services | Director/Board Member | |
Sophion Bioscience A/S
 Sophion Bioscience A/S Medical SpecialtiesHealth Technology Sophion Bioscience A/S develops, manufactures and markets instruments and supplies automated patch clamping. It develops throughput patch clamp solutions for functional characterization of living cells. The firm products are used in pharmaceutical and biotech companies around the world. The company was founded in July 2007 and is headquartered in Ballerup, Denmark. | Medical Specialties | Chairman | |
| PCI BIOTECH HOLDING ASA | Biotechnology | Director/Board Member | |
| CHEMOMETEC A/S | Medical Specialties | Director/Board Member | |
| NTG NORDIC TRANSPORT GROUP A/S | Trucking | Corporate Officer/Principal | |
7TM A/S
 7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Pharmaceuticals: Major | Chief Executive Officer | |
| Plougmann, Vingtoft & Partners A/S | Corporate Officer/Principal | ||
Symbion A/S
 Symbion A/S General GovernmentGovernment Symbion A/S provides office communities, meeting facilities, conference facilities, business development and capital for start-up companies. The company was founded in 1986 and is headquartered in Copenhagen, Denmark. | General Government | Director/Board Member | |
Labrida AS
 Labrida AS Medical SpecialtiesHealth Technology Labrida AS provides novel device for maintenance of dental implants. The company was founded by Johan C. Wohlfahrt and Staale Petter Lyngstadaas in August 2012 and is headquartered in Oslo, Norway. | Medical Specialties | Director/Board Member | |
KLIFO A/S
 KLIFO A/S Miscellaneous Commercial ServicesCommercial Services KLIFO A/S provides clinical research services. Its services include development plans, protocols, project management, monitoring, data management and statistics, reporting, regulatory affairs, importing, packaging, labeling, and distribution of clinical trials. The company provides services to the pharmaceutical and medical devices industries. KLIFO was founded by Dr. Allan Rosetzsky in 1994 and is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Chairman | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member | |
| ANTARES PHARMA, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
| GN STORE NORD A/S | Telecommunications Equipment | Corporate Officer/Principal | |
MSD (Norge) AS
 MSD (Norge) AS Pharmaceuticals: MajorHealth Technology MSD (Norge) AS operates as research-based company that researches and develops new drugs. It offers pharmaceutical products, medical equipment, technical products, and other healthcare products and substances. The company is headquartered in Drammen, Norway. | Pharmaceuticals: Major | President | |
| TRAVERE THERAPEUTICS, INC. | Pharmaceuticals: Major | General Counsel | |
K36 Therapeutics, Inc.
 K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | Pharmaceuticals: Major | Director/Board Member | |
Fritz Schur Technical Group A/S
 Fritz Schur Technical Group A/S Wholesale DistributorsDistribution Services Part of FS 12 ApS, Fritz Schur Technical Group A/S is a Danish company that supplies industrial equipment. The company is based in Albertslund, Denmark. The CEO of the company is Mads-Ole Astrupgaard. | Wholesale Distributors | Director of Finance/CFO | |
| Silicon Labs Denmark | Director of Finance/CFO | ||
| SCANDION ONCOLOGY A/S | Pharmaceuticals: Major | Director of Finance/CFO | |
| Royal Hibernian Academy | College/University | Graduate Degree | |
| Caldwell College | College/University | Undergraduate Degree | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Eterna Therapeutics LLC
 Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | Pharmaceuticals: Major | Chief Executive Officer | |
| ETERNA THERAPEUTICS INC. | Pharmaceuticals: Major | Chief Executive Officer | |
| PFIZER, INC. | Pharmaceuticals: Major | Director/Board Member | |
| ARCTICZYMES TECHNOLOGIES ASA | Medical Specialties | President | |
GN Hearing A/S
 GN Hearing A/S Medical SpecialtiesHealth Technology GN Hearing A/S develops and sells hearings aids and tools for measuring loss of hearing capability. It provides solutions for all types of ear-related diagnostics and distributes computerized audiology and hearing-instrument fitting equipment. The company was founded in 1957 and is headquartered in Ballerup, Denmark. | Medical Specialties | Chief Executive Officer | |
| Statens Serum Institute | College/University | Director/Board Member | |
| University of Oslo | College/University | Doctorate Degree | |
Lundbeckfonden Ventures
 Lundbeckfonden Ventures Investment ManagersFinance Lundbeckfonden Ventures (Lundbeckfonden Ventures) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2009 and is headquartered in Copenhagen, Denmark. | Investment Managers | Private Equity Investor | |
Thesan Pharmaceuticals, Inc.
 Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA. | Pharmaceuticals: Major | Director/Board Member | |
| HARBOES BRYGGERI A/S | Beverages: Alcoholic | Director/Board Member | |
ValSource LLC
 ValSource LLC Pharmaceuticals: MajorHealth Technology ValSource LLC provides consulting and advisory services to the pharmaceutical, advanced therapy medicinal products, biologics, and medical device industries. The private company is based in Downingtown, PA. The company's services aim to ensure the success and speed-to-market of client projects. | Pharmaceuticals: Major | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 23 |
| Dänemark | 22 |
| Norwegen | 6 |
| Kanada | 2 |
| Irland | 2 |
Sektoral
| Health Technology | 32 |
| Consumer Services | 8 |
| Commercial Services | 3 |
| Electronic Technology | 3 |
| Process Industries | 2 |
Operativ
| Director/Board Member | 95 |
| Independent Dir/Board Member | 37 |
| Corporate Officer/Principal | 35 |
| Chief Executive Officer | 28 |
| President | 22 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Mette Agger | 30 |
| Paul Wotton | 27 |
| Thomas Dyrberg | 24 |
| Michael Heffernan | 23 |
| Craig Collard | 18 |
| Robert Radie | 18 |
| Alastair Stuart McEwan | 12 |
| Ronald Guido | 9 |
| Lars Kåre Viksmoen | 9 |
| Johnny Stilou | 7 |
| Ira Duarte | 7 |
| Morten Marott | 5 |
| Noel Barnard | 4 |
| Breian Knudsen | 3 |
| Ulf Meier-Kriesche | 2 |
- Börse
- Insiders
- Stacy Wheeler
- Unternehmensverbindungen
